Drug Trial Radar · NCT07285460
A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B
Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
85
Planned (sponsor's estimate)
Start
Dec 18, 2025
Primary completion
Aug 4, 2029
Study completion Dec 30, 2031
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Dec 16, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 1 year, up to 11 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a parallel, Phase 3, two-arm, open-label study to evaluate the efficacy and safety of treatment with fitusiran prophylaxis administered to male pediatric participants (aged 1 to \<12 years) who have severe hemophilia A or B, with or without inhibitory antibodies to FVIII or FIX. Number of participants: Approximately 85 participants will be enrolled into the study: * Approximately 60 fitusiran-naïve participants with severe hemophilia A or B, with or without inhibitors (fitusiran-naïve arm), and * Approximately 25 participants with severe hemophilia A or B with inhibitors rolling over from the EFC15467\* dose confirmation study (roll-over arm). * Fitusiran has been investigated in the pediatric population in study EFC15467, which enrolled male participants aged 1 to \<12 years with hemophilia A or B with inhibitors to examine the safety and tolerability of fitusiran in the pediatric population. Participants will be enrolled into 1 of 2 arms: * Fitusiran-naïve: these participants have not previously received fitusiran, and they will undergo screening and study eligibility assessments. Once enrolled, they will go through a 24-week standard of care (SOC) period before starting fitusiran prophylaxis. * Roll-over participants from the EFC15467 study: only participants who are still on active treatment in study EFC15467 and consenting to study EFC17905 will be eligible to roll over. They will not need to undergo screening or further eligibility assessments. They will directly enroll into the fitusiran treatment period and continue treatment on their current fitusiran dose. The duration of fitusiran treatment will be up to 160 weeks for the fitusiran-naïve arm and up to 60 weeks for the roll-over arm.
Conditions
- Hemophilia
Interventions
FitusiranDrug
Pharmaceutical form: solution for injection in PBS Route of administration: subcutaneous
Clotting factor concentrates (CFC) or bypassing agents (BPA)Biological
Pharmaceutical form: solution for injection Route of administration: intravenous injection
Antithrombin concentrate (ATIIIC)Biological
Pharmaceutical form: solution for injection Route of administration: intravenous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized treated bleeding rate (ABR) in the fitusiran primary efficacy period and in the SOC periodTime frame: Day 85 to Day 421 (fitusiran primary efficacy period); Day -168 to Day -1 (SOC period)
Locations
37 sites in 12 countries. Site status is shown where the registry gives one.
The Luskin Orthopaedic Institute for Children- Site Number : 8400013
Los Angeles, California · Recruiting
Children's Hospital Los Angeles- Site Number : 8400002
Los Angeles, California · Recruiting
The Center for Inherited Blood Disorders- Site Number : 8400009
Orange, California · Recruiting
UCLA Medical Center - Harbor- Site Number : 8400011
Torrance, California · Recruiting
University of Michigan Health System - Ann Arbor- Site Number : 8400003
Ann Arbor, Michigan · Recruiting
Cure 4 The Kids Foundation- Site Number : 8400001
Las Vegas, Nevada · Recruiting
Hackensack Meridian Health - Hackensack University Medical Center- Site Number : 8400008
Hackensack, New Jersey · Recruiting
University of Texas - Southwestern Medical Center- Site Number : 8400015
Dallas, Texas · Recruiting
Investigational Site Number : 0560002
Brussels, Belgium · Recruiting
Investigational Site Number : 0560001
Brussels, Belgium · Recruiting
Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo- Site Number : 0760004
São Paulo, Brazil · Recruiting
Universidade Estadual de Campinas (UNICAMP)- Site Number : 0760001
Campinas, São Paulo, Brazil · Recruiting
Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto- Site Number : 0760003
Ribeirão Preto, São Paulo, Brazil · Recruiting
Investigational Site Number : 1240001
Hamilton, Ontario, Canada · Recruiting
Investigational Site Number : 1240005
Toronto, Ontario, Canada · Recruiting
Investigational Site Number : 1240003
Montreal, Quebec, Canada · Recruiting
Investigational Site Number : 1560001
Beijing, China · Recruiting
Investigational Site Number : 1560002
Wuhan, China · Recruiting
Investigational Site Number : 3560004
Bengaluru, India · Recruiting
Investigational Site Number : 3560002
Mumbai, India · Recruiting
Investigational Site Number : 3560001
Pune, India · Recruiting
Investigational Site Number : 3560003
Vellore, India · Recruiting
Investigational Site Number : 3800002
Florence, Firenze, Italy · Recruiting
Investigational Site Number : 3800001
Milan, Milano, Italy · Recruiting
Investigational Site Number : 3800003
Rozzano, Milano, Italy · Recruiting
Investigational Site Number : 6160003
Poznan, Greater Poland Voivodeship, Poland · Recruiting
Klinika Transplantacji Szpiku, Onkologii i Hematologii Dziecięcej - Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wrocławiu-Site Number: 6160002
Wroclaw, Lower Silesian Voivodeship, Poland · Recruiting
Investigational Site Number : 6160001
Warsaw, Masovian Voivodeship, Poland · Recruiting
Investigational Site Number : 6820002
Dammam, Saudi Arabia · Recruiting
Investigational Site Number : 6820001
Riyadh, Saudi Arabia · Recruiting
Investigational Site Number : 7240003
Zaragoza, Aragon, Spain · Recruiting
Investigational Site Number : 7240001
Esplugues de Llobregat, Barcelona [Barcelona], Spain · Recruiting
Investigational Site Number : 7240002
Madrid, Madrid, Comunidad de, Spain · Recruiting
Department of pediatrics, Chung Shan University Hospital-Site Number : 1580002
Taichung, Taiwan · Recruiting
The division of Hematology, National Taiwan University Hospital-Site Number : 1580001
Taipei City, Taipei, Taiwan · Recruiting
Investigational Site Number : 7920001
Istanbul, Turkey (Türkiye) · Recruiting
Investigational Site Number : 7920002
Izmir, Turkey (Türkiye) · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.